Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir

Author:

Ford Emily S12ORCID,Simmons William1,Karmarkar Ellora N1,Yoke Leah H12,Braimah Ayodale B3,Orozco Johnnie J45,Ghiuzeli Cristina M46,Barnhill Serena7,Sack Coralynn L7,Benditt Joshua O7,Roychoudhury Pavitra28,Greninger Alexander L28,Shapiro Adrienne E129,Hammond Jennifer L10,Rusnak James M10,Dolsten Mikael10,Boeckh Michael124,Liu Catherine124,Cheng Guang-Shing247,Corey Lawrence1248

Affiliation:

1. Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington , Seattle, Washington , USA

2. Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington , USA

3. Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, Washington , USA

4. Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington , USA

5. Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington , USA

6. Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington , USA

7. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington , USA

8. Department of Laboratory Medicine, University of Washington, Seattle, Washington , USA

9. Department of Global Health, University of Washington, Seattle, Washington , USA

10. Pfizer , New York, NY , USA

Abstract

AbstractA patient with B-cell acute lymphoblastic leukemia (ALL) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia with viremia after 5 months of infection despite monoclonal antibodies, intravenous (IV) remdesivir and prolonged oral steroids. Twenty days of nirmatrelvir/ritonavir and 10 days of IV remdesivir led to full recovery.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3